LB Pharmaceuticals CMO Anna Eramo resigns; will advise through September 15, 2026

LB PHARMACEUTICALS INC

Anna Eramo, M.D., resigns as CMO effective June 15, 2026; transitions to advisor role through Sept 15, 2026.
Separation agreement includes base salary until June 15, 2027, prorated 2026 bonus, and accelerated vesting of 66,143 options.
Company states departure is unrelated to clinical operations and expects no material impact on clinical milestones.
Search for replacement underway; existing clinical teams will continue to oversee ongoing trials.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Anna Eramo

Chief Medical Officer

LBRX · LB PHARMACEUTICALS INC

Effective: 2026-06-15
Filed: June 10, 2026, 4:16 PM ET

On June 8, 2026, she resigned from her position as Chief Medical Officer of the Company effective June 15, 2026 (the " Separation Date ").

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Anna Eramo resigned as Chief Medical Officer at LB PHARMACEUTICALS INC.

Action: resigned
Role: Chief Medical Officer

Exact text from the filing

On June 8, 2026, she resigned from her position as Chief Medical Officer of the Company effective June 15, 2026 (the " Separation Date ").

View on SEC.gov

LB PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001193125-26-265867

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.